Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares Repurchased
Ratios

Ligand Pharmaceuticals (LGND) EBIAT (2016 - 2025)

Ligand Pharmaceuticals' EBIAT history spans 16 years, with the latest figure at $44.8 million for Q4 2025.

  • For Q4 2025, EBIAT rose 244.06% year-over-year to $44.8 million; the TTM value through Dec 2025 reached $118.3 million, up 3034.77%, while the annual FY2025 figure was $124.5 million, 3186.63% up from the prior year.
  • EBIAT for Q4 2025 was $44.8 million at Ligand Pharmaceuticals, down from $117.3 million in the prior quarter.
  • Across five years, EBIAT topped out at $117.3 million in Q3 2025 and bottomed at -$51.9 million in Q2 2024.
  • The 5-year median for EBIAT is $697500.0 (2022), against an average of $10.2 million.
  • The largest annual shift saw EBIAT crashed 2366.86% in 2024 before it surged 1735.15% in 2025.
  • A 5-year view of EBIAT shows it stood at -$5.4 million in 2021, then crashed by 393.37% to -$26.7 million in 2022, then surged by 174.28% to $19.9 million in 2023, then plummeted by 256.59% to -$31.1 million in 2024, then skyrocketed by 244.06% to $44.8 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's EBIAT are $44.8 million (Q4 2025), $117.3 million (Q3 2025), and -$1.3 million (Q2 2025).